Navigation Links
FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
Date:9/5/2009

SEATTLE, Sept. 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has notified CTI that a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2010 under standard review has been established regarding CTI's NDA for pixantrone as potential treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). Pixantrone has fast track designation for the relapsed / refractory aggressive NHL application.

"The 18 month follow up PIX 301 pivotal trial data continues to demonstrate further improvement in primary and secondary endpoints including Complete Remission / Complete Remission unconfirmed(CR/CRu), Progression Free Survival (PFS) and Overall Survival over standard chemotherapy. We look forward to providing the four month safety and efficacy update to the FDA and working with them toward potential approval," said James A. Bianco, M.D., Chief Executive Officer of CTI.

Based on the user fee goal date, if pixantrone is approved, CTI estimates that pixantrone could be available to patients in the U.S. early in the second quarter of 2010.

About Pixantrone

Pixantrone (BBR 2778), is a novel topoisomerase II inhibitor with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. '/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Real-World Study Showed Cost Savings for VTE Prophylaxis with Enoxaparin Compared with Unfractionated Heparin (UFH)
2. Mars, Incorporated Commits Over $2 Million to Federal Agency for Human-Animal Interaction Research
3. Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
4. Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
5. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
6. ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer
7. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
8. APTA Supports Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
9. Surgeon Generals Call to Action to Prevent DVT/PE Praised by NATT as Turning Point
10. U.S. FDA Issues Action Letter for Sugammadex
11. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Celsion Corporation (the "Company") (NASDAQ: CLSN ... institutional investors to purchase an aggregate of approximately $15 ... registered direct offering, led by a dedicated health care ... agreements with these investors pursuant to which the Company ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 Shire plc ... waived the Office of Fair Trading (OFT) approval condition to the ... Incorporated (NASDAQ: VPHM).   As a result of the ... Shire expects to complete the tender offer on January 24, 2014 ...
(Date:1/15/2014)... , January 15, 2014 BreedIT ... the exclusive worldwide distributor of highly sophisticated agro-breeding solutions ... January 7, 2014, the Company,s board of directors appointed ... as its new member of the board. ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Bolder BioTechnology, Inc. today announced that it has ... (SBIR) grant totaling $600,000 from the National Institute of ... of Health (NIH).  The grant will be used to ... analog to accelerate platelet recovery and improve survival in ...
... Technologies Foster Better Informed Consumers, Greater Interest in Personal... -- PHILADELPHIA, Pennsylvania, August 18, 2010 ... ... lpUnit=,PRN,; --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
Cached Medicine Technology:Bolder BioTechnology Announces $600,000 Grant from NIH to Study Long-Acting IL-11 Analog in Treating Acute Radiation Syndrome 2Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 2Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 3Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 4Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 5Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 6Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 7Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 8
(Date:4/17/2014)... the first genetic variant specifically associated with the ... around 10-15 per cent of all breast cancer ... breast cancer sub-type, called invasive lobular carcinoma, gives ... this particular kind of breast cancer, which can ... today (Thursday) in the journal PloS Genetics ...
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
(Date:4/17/2014)... Jon McCullers, MD, was recently invited to submit ... Nature Reviews Microbiology , one of the world,s ... infectious disease specialist, and chair of the Department ... Science Center, analyzed the epidemiology and microbiology of ... as well as more recent 2009 novel H1N1 ...
(Date:4/17/2014)... It,s estimated that as many as 10 million older ... of loneliness and isolation. , However, new research ... retired older Americans for six years found that ... of depression by more than 30 percent. , "That,s ... State University professor of telecommunication, information studies and media ...
(Date:4/17/2014)... from Boston University School of Medicine (BUSM) have ... consumption in an experimental model. The findings, reported ... Alcohol Abuse , may lead to more effective ... is one of the leading causes of illness ... negative economic impact by limiting the productivity of ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... damage to DNA, study says , , THURSDAY, Dec. ... at risk of DNA damage from prolonged exposure to ... 83 airline pilots to 50 university faculty members from ... participants were analyzed for DNA abnormalities, specifically the number ...
... teens is slowing, survey finds , , THURSDAY, Dec. 11 (HealthDay ... teens, the abuse of painkillers such as Vicodin and Oxycontin ... in the use of drugs such as marijuana has stalled ... Institute on Drug Abuse says in its report, Monitoring ...
... The American Academy of Orthopaedic Surgeons (AAOS) has ... of Osteoarthritis of the Knee". These guidelines were explicitly ... knee replacement surgery. While a wide range of treatment ... patients after discussions with their physicians. , ...
... Growth Equities, Ltd. initiates coverage of PolyMedix Inc. (OTC ... $9.00 price target. PolyMedix focuses on developing novel ... The Company,s leading clinical development programs include the ... , , Emerging Growth ...
... President & CEO , , ... a drug delivery technology company, today announced that George DeMott, chairman ... position as chairman, effective immediately. Mr. DeMott will continue to ... , , The board of directors ...
... serious risk of a long-term hospital stay, and ventilator-associated ... 15% of all people who are ventilated, is among ... a higher resistance to antibiotics, patients who rely on ... as 26,000 Americans do every year. , Thanks to ...
Cached Medicine News:Health News:Pilots May Face Greater Cancer Risk 2Health News:10% of U.S. High School Seniors Use Vicodin 2Health News:10% of U.S. High School Seniors Use Vicodin 3Health News:AAOS Issues New Clinical Practice Guideline for Osteoarthritis of the Knee 2Health News:AAOS Issues New Clinical Practice Guideline for Osteoarthritis of the Knee 3Health News:Emerging Growth Equities, Ltd. Initiates Coverage of PolyMedix Inc. With a Buy Rating and a $9.00 Price Target 2Health News:DelSite Chairman George DeMott Resigns 2Health News:DelSite Chairman George DeMott Resigns 3Health News:There's a life-saving medical device sitting on your sink 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: